DIAMANTE Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles
- Coordinator
- Diamante Societa Benefit S.r.l, Italy
- Runs
- 1 January 2025 to 31 December 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101189019
What the project is doing
In the project's own words, from its summary on CORDIS.
At Diamante Società Benefit srl we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP). Our patented protected VNPs’ mode of action is based on Antigen Specific Immunotehrapy. This means that our VNPs are able to re-educate the immune system to immune tolerate the specific body’s own cell (autoantigen) causing the disease.
Our Proof-of-concept studies in Rheumatoid Arthritis (RA - our first indication) animal models have shown complete remission of arthritic symptoms. Currently, there is no cure or preventive measure for this chronic condition; first-line treatments revolve around immunosuppression, causing several side effects. Our drug will be the first treatment based on the restoration of self-tolerance, while maintaining the immune system’s ability to defend itself; hence reducing potential harmful side effects.
We are now seeking funding to cover the next clinical development steps.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Diamante Societa Benefit S.r.l | Verona | Italy | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI